Intellia Therapeutics Community

NasdaqGM:NTLA Community

1 Narratives written by author
0 Comments on narratives written by author
62 Fair Values set on narratives written by author

Intellia Therapeutics

AN

AnalystConsensusTarget

Consensus Narrative from 27 Analysts

Phase III Trials And Gene Editing Will Bring Promising Therapies

Key Takeaways Strategic discontinuation of less promising programs and capital prioritization are expected to improve net margins and enhance commercial prospects. Promising therapies in Phase III studies are poised to drive revenue growth and market share capture upon expected launches between 2027 and 2030.

US$42.85

FV

80.9% undervalued

78.50%

Revenue growth p.a.

1

0

52

Updated